Tamez-Pérez HE, Gutiérrez-Hermosillo H, Forsbach-Sánchez G, Gómez-de Ossio MD, González-González G, Guzmán-López S, Tamez-Peña AL, Mora-Torres NE, González–Murillo EA

Language: English
References: 15
Page: 180-183
PDF size: 47.56 Kb.

ABSTRACT

Background. Fine-Needle Aspiration (FNA) is the main screening process for distinguishing benign from malignant thyroid nodules. Despite this, by 5-29% of patients, their FNA results are not enough to confírm malign neoplasia, particularly in cases with follicular lesions. The objective of this report is to present the definitive histological results of a group of 41 patients with FNA of Thyroid nodule catalogued as “indeterminate/non diagnostic” sent for surgical treatment. Material and methods. A retrospective analysis was done on all of the patients who had underwent surgery for thyroid nodule, with a previous diagnosis of “indeterminate/non diagnostic” by FNA. Forty-one patients, three male (7.31%), and 38 female (92.68%), were included in the present study. Results. Fifteen women and one man were positive for malignancies (39.02%). The nodule was bigger than 4 cm in 23 patients in total (56.09%), and of this percentage, 6 were malignant (26.09%). According to age, 24 patients were older than 45 years (58.5%), 8 of whom showed malignant pathology (33.3%). All these variables were non significant. Fifteen of 16 patients had a definitive diagnosis of papillary carcinoma and one follicular carcinoma. Conclusions. The majority of patients with a diagnosis of “indeterminated/non diagnostic” had benign lesions (60.9%). The usual predictive factors for malignity such as age, sex, size of nodule, did not present a significant support in the differential diagnosis.

REFERENCES

1. Castro M, Castro MD, Hossein G. Continuing Controversies in the Management of Thyroid Nodules. Ann Intern Med 2005; 142: 926-31.

2. AACE/AME Task Force on Thyroid Nodules. Endocr Pract 2006; 12: 63-102.

3. Hegedus L. Clinical practice: the thyroid nodule. N Engl J Med 2004; 351: 1764-71.

4. Chow LS, Gharib H, Goellener JR, van Heerden JA. Non diagnostic thyroid fine needle aspiration cytology: management dilemmas. Thyroid 2001; 11: 1147-51.

5. Saggiorato E, Cappia S, De Giuli P, Mussa A. Galectin 3 as a presurgical inmunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin End Met 2001; 86: 5152-8.

6. Hegedus L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter; current status and future perspectives. Endocr Rcv 2003; 24: 102-32.

7. Stephenson TJ. Prognostic and predictive factors in endocrine tumours. Histopathology 2006; 48: 629-43.

8. Sherman S. Thyroid carcinoma. Lancet 2003; 361: 501-11.

9. Greaves T, Olvera M, Florentine B, Raza A. Follicular Lesiones of thyroid, a 5 year fine needle aspiration experience. Cáncer Cytopathol 2000; 90: 337-41.

10. Kovacs RB, Foldes J, Winkler G, Bodo M, Sapi Z. The investigation of Galectin 3 in diseases of the thyroid gland. Eur J End 2003; 149: 449-53.

11. Sahin M, Gursoy A, Tutuncu NB, Guvener N. Prevalence and prediction of malignancy in cytologically indeterminate thyroid nodules. Clinical Endocrinology 2006; 65: 514-18.

12. Bartolazzi A, Papotti M, Bussolatt G. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001; 357: 1644-50.

13. Bernet V, Anderson J, Vaishnav Y, Salomon B. Determination of Galectin 3 messenger ribonucleic acid overexpression in papillary thyroid cancer by quantitative reverse transcription polymerase chain reaction. J Clin End Metab 2002; 87: 4792-6.

14. Coli A, Bigotti G, Zucchetti F. Galectin 3, a marker of well differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology 2002; 40: 80-7.

15. Sebo JT, Castro MR, Gharib H. Thyroid nodules: a systematic and cost-effective approach. Endocrinology Update 2006; 1: 3-4.